Diagnosis and treatment of myasthenia gravis

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewThis article provides an update on the most recent advances in diagnostic procedures and therapeutic approaches for myasthenia gravis, spanning from autoantibody and neuroelectrophysiological tests as diagnostic tools, to innovative and promising treatments based on biological drugs.Recent findingsNovel studies performed by cell-based assays (CBAs) indicate an improvement in the chance of identifying serum autoantibodies in myasthenic patients. Clinical trials on the use of biological drugs were recently concluded, providing important data on safety and efficacy of eculizumab, efgartigimod and amifampridine phosphate: The first, a complement blocker, showed long-term safety and efficacy in acetylcholine receptor (AChR)-positive myasthenic patients with refractory generalized disease; the second, the neonatal Fc receptor blocker, was well tolerated and clinically effective in both AChR-specific and muscle-specific kinase receptor (MuSK)-positive patients; the third, a blocker of presynaptic potassium channels, was found to be well tolerated and effective in MuSK-positive patients.SummaryCBAs can lead to a significant reduction of seronegative patients, improving myasthenia gravis diagnostic process. New biological drugs offer innovative approaches to treat myasthenic patients with generalized disease, promising to change the paradigm of treatment and to significantly enhance therapeutic success within a precision medicine framework.

Original languageEnglish
Pages (from-to)623-633
Number of pages11
JournalCurrent Opinion in Rheumatology
Issue number6
Publication statusPublished - Nov 1 2019


  • autoantibodies
  • biologic agents
  • immunosuppressive drugs
  • myasthenia gravis
  • precision medicine

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Diagnosis and treatment of myasthenia gravis'. Together they form a unique fingerprint.

Cite this